Advanced in Essential Thrombocythemia

Dr. Hong Zhao

Hematology Oncology | Hematology | Oncology
County Of Monterey
1441 Constitution Blvd, 
Salinas, CA 
Clinical Trials:Currently Recruiting for 1 Trial
Offers Telehealth
Advanced in Essential Thrombocythemia
County Of Monterey
1441 Constitution Blvd, 
Salinas, CA 
OverviewInsuranceLocationsClinical ResearchSimilar Doctors

Overview

Hong Zhao is a Hematologist Oncology specialist and a Hematologist in Salinas, California. Dr. Zhao is rated as an Advanced provider by MediFind in the treatment of Essential Thrombocythemia. Her top areas of expertise are Familial Colorectal Cancer, Thrombocytopenia, Anemia, Paget Disease of the Breast, and Bone Marrow Aspiration.

Her clinical research consists of participating in 7 clinical trials. MediFind looks at clinical research from the past 15 years.

Specialties
Hematology Oncology
Hematology
Oncology
Licenses
Internal Medicine in PA
Hospital Affiliations
Salinas Valley Memorial Hospital
Natividad Medical Center
Hazel Hawkins Memorial Hospital
Southern Monterey County Memorial Hospital
Languages Spoken
English
Gender
Female

Insurance

Accepted insurance can change. Please verify directly with the provider.

Find your insurance
Find your insuranceClose

Accepted insurance plans:

Aetna
  • EPO
  • HMO
  • POS
  • PPO
Anthem
  • EPO
  • HMO
  • POS
  • PPO
Blue Shield of California
  • HMO
  • INSURANCE PLAN
  • MANAGED MEDICAID PLAN
  • MEDICARE MAPD
  • MEDICARE PDP
  • MEDICARE-MEDICAID PLAN
  • OTHER COMMERCIAL
  • OTHER MEDICARE
  • OTHER MEDICARE PART D
  • PPO
Cigna
  • EPO
  • HMO
  • PPO
Health Care Services Corporation
  • HMO
  • INSURANCE PLAN
  • MANAGED MEDICAID PLAN
  • MEDICARE MAPD
  • MEDICARE PDP
  • MEDICARE SNP
  • OTHER COMMERCIAL
  • OTHER MEDICARE
  • OTHER MEDICARE PART D
  • PPO
Humana
  • HMO
  • INDEMNITY
  • POS
  • PPO
Managed Medicaid
  • OTHER MANAGED MEDICAID
Medicaid
  • OTHER MEDICAID
  • STATE MEDICAID
UnitedHealthcare
  • EPO
  • HMO
  • POS
  • PPO
Wellcare
  • EPO
  • HMO
  • INSURANCE PLAN
  • MANAGED MEDICAID PLAN
  • MEDICARE MAPD
  • MEDICARE PDP
  • MEDICARE SNP
  • MEDICARE-MEDICAID PLAN
  • OTHER MEDICARE
  • OTHER MEDICARE PART D
View 5 Less Insurance Carriers -

Locations

COUNTY OF MONTEREY
1441 Constitution Blvd, Salinas, CA 93906
Other Locations
COUNTY OF MONTEREY
1270 Natividad Rd, 146.38, Salinas, CA 93906
COUNTY OF MONTEREY
1615 Bunker Hill Way, Suite 100, Salinas, CA 93906

Clinical Research

Clinical research consists of overseeing clinical studies of patients undergoing new treatments and therapies, and publishing articles in peer reviewed medical journals. Providers who actively participate in clinical research are generally at the forefront of the fields and aware of the most up-to-date advances in treatments for their patients.

7 Clinical Trials

Randomized Phase III Study of Combination Osimertinib (AZD9291) and Bevacizumab Versus Osimertinib (AZD9291) Alone as First-Line Treatment for Patients With Metastatic EGFR-Mutant Non-Small Cell Lung Cancer (NSCLC)
Randomized Phase III Study of Combination Osimertinib (AZD9291) and Bevacizumab Versus Osimertinib (AZD9291) Alone as First-Line Treatment for Patients With Metastatic EGFR-Mutant Non-Small Cell Lung Cancer (NSCLC)
Enrollment Status: Recruiting
Publish Date: October 10, 2025
Intervention Type: Procedure, Drug, Biological
Study Drugs: Bevacizumab, Osimertinib
Study Phase: Phase 3
Randomized, Double-Blinded Phase III Study of CABozantinib Versus Placebo IN Patients With Advanced NEuroendocrine Tumors After Progression on Prior Therapy (CABINET)
Randomized, Double-Blinded Phase III Study of CABozantinib Versus Placebo IN Patients With Advanced NEuroendocrine Tumors After Progression on Prior Therapy (CABINET)
Enrollment Status: Active_not_recruiting
Publish Date: October 08, 2025
Intervention Type: Other, Procedure, Drug
Study Drug: Cabozantinib S-malate
Study Phase: Phase 3
A Phase III, Randomized Clinical Trial of Standard Adjuvant Endocrine Therapy +/- Chemotherapy in Patients With 1-3 Positive Nodes, Hormone Receptor-Positive and HER2-Negative Breast Cancer With Recurrence Score (RS) of 25 or Less. RxPONDER: A Clinical Trial Rx for Positive Node, Endocrine Responsive Breast Cancer
A Phase III, Randomized Clinical Trial of Standard Adjuvant Endocrine Therapy +/- Chemotherapy in Patients With 1-3 Positive Nodes, Hormone Receptor-Positive and HER2-Negative Breast Cancer With Recurrence Score (RS) of 25 or Less. RxPONDER: A Clinical Trial Rx for Positive Node, Endocrine Responsive Breast Cancer
Enrollment Status: Active_not_recruiting
Publish Date: September 22, 2025
Intervention Type: Drug, Other
Study Drugs: Anastrozole, Exemestane, Letrozole, Systemic Chemotherapy
Study Phase: Phase 3
(CompassHER2-pCR): Preoperative THP and Postoperative HP in Patients Who Achieve a Pathologic Complete Response
(CompassHER2-pCR): Preoperative THP and Postoperative HP in Patients Who Achieve a Pathologic Complete Response
Enrollment Status: Active_not_recruiting
Publish Date: April 18, 2025
Intervention Type: Procedure, Biological, Drug, Radiation
Study Drugs: Docetaxel, Nab-Paclitaxel, Paclitaxel, Pertuzumab, Trastuzumab, Trastuzumab Emtansine
Study Phase: Phase 2
A Randomized Phase III Trial Comparing Axillary Lymph Node Dissection to Axillary Radiation in Breast Cancer Patients (cT1-3 N1) Who Have Positive Sentinel Lymph Node Disease After Neoadjuvant Chemotherapy
A Randomized Phase III Trial Comparing Axillary Lymph Node Dissection to Axillary Radiation in Breast Cancer Patients (cT1-3 N1) Who Have Positive Sentinel Lymph Node Disease After Neoadjuvant Chemotherapy
Enrollment Status: Active_not_recruiting
Publish Date: January 13, 2025
Intervention Type: Radiation, Procedure
Study Phase: Phase 3
Phase III Randomized, Placebo-Controlled Clinical Trial Evaluating the Use of Adjuvant Endocrine Therapy +/- One Year of Everolimus in Patients With High-Risk, Hormone Receptor-Positive and HER2/Neu Negative Breast Cancer
Phase III Randomized, Placebo-Controlled Clinical Trial Evaluating the Use of Adjuvant Endocrine Therapy +/- One Year of Everolimus in Patients With High-Risk, Hormone Receptor-Positive and HER2/Neu Negative Breast Cancer
Enrollment Status: Active_not_recruiting
Publish Date: December 27, 2024
Intervention Type: Drug, Other
Study Drugs: Anastrozole, Everolimus, Exemestane, Goserelin Acetate, Letrozole, Leuprolide Acetate, Tamoxifen Citrate
Study Phase: Phase 3
A Randomized Phase III Trial of Adjuvant Therapy Comparing Doxorubicin Plus Cyclophosphamide Followed by Weekly Paclitaxel With or Without Carboplatin for Node-Positive or High-Risk Node-Negative Triple-Negative Invasive Breast Cancer
A Randomized Phase III Trial of Adjuvant Therapy Comparing Doxorubicin Plus Cyclophosphamide Followed by Weekly Paclitaxel With or Without Carboplatin for Node-Positive or High-Risk Node-Negative Triple-Negative Invasive Breast Cancer
Enrollment Status: Active_not_recruiting
Publish Date: June 03, 2024
Intervention Type: Drug, Other
Study Drugs: Carboplatin, Cyclophosphamide, Doxorubicin Hydrochloride, Paclitaxel
Study Phase: Phase 3
View 6 Less Clinical Trials
Similar Doctors
Elite in Essential Thrombocythemia
Dr. Jason R. Gotlib
Hematology
Elite in Essential Thrombocythemia
Dr. Jason R. Gotlib
Hematology

Stanford Medicine Cancer Center

875 Blake Wilbur Dr, 
Palo Alto, CA 
 (59.2 miles away)
650-498-6000
Languages Spoken:
English
See accepted insurances
Accepting New Patients
Offers Telehealth

Jason Gotlib is a Hematologist in Palo Alto, California. Dr. Gotlib is rated as an Elite provider by MediFind in the treatment of Essential Thrombocythemia. His top areas of expertise are Systemic Mastocytosis, Mast Cell Activation Syndrome (MCAS), Myelofibrosis, Bone Marrow Aspiration, and Tissue Biopsy. Dr. Gotlib is currently accepting new patients.

Distinguished in Essential Thrombocythemia
Dr. Peter S. Galatin
Oncology | Hematology | Hematology Oncology
Distinguished in Essential Thrombocythemia
Dr. Peter S. Galatin
Oncology | Hematology | Hematology Oncology

Stanford Health Care

300 Pasteur Dr, 
Stanford, CA 
 (59.0 miles away)
650-723-4000
Languages Spoken:
English
See accepted insurances
Offers Telehealth

Peter Galatin is an Oncologist and a Hematologist in Stanford, California. Dr. Galatin is rated as a Distinguished provider by MediFind in the treatment of Essential Thrombocythemia. His top areas of expertise are Polycythemia Vera, Essential Thrombocythemia, Chronic Lymphocytic Leukemia (CLL), and Small Lymphocytic Lymphoma (SLL).

Advanced in Essential Thrombocythemia
Dr. William Shomali
Hematology | Oncology | Hematology Oncology
Advanced in Essential Thrombocythemia
Dr. William Shomali
Hematology | Oncology | Hematology Oncology

Stanford Health Care

300 Pasteur Dr, 
Stanford, CA 
 (59.0 miles away)
650-723-4000
Experience:
16+ years
Languages Spoken:
English
See accepted insurances
Offers Telehealth

William Shomali is a Hematologist and an Oncologist in Stanford, California. Dr. Shomali has been practicing medicine for over 16 years and is rated as a Distinguished provider by MediFind in the treatment of Essential Thrombocythemia. His top areas of expertise are Systemic Mastocytosis, Mast Cell Activation Syndrome (MCAS), Acute Myeloid Leukemia (AML), Chronic Myelogenous Leukemia (CML), and Bone Marrow Aspiration.

Areas of Expertise

MediFind evaluates expertise by pulling from factors such as number of articles a doctor has published in medical journals, participation in clinical trials, speaking at industry conferences, prescribing and referral patterns, and strength of connections with other experts in their field.

Learn more about MediFind’s expert tiers

Find Dr. Zhao's expertise for a condition
ConditionClose
    View All 9 Distinguished Conditions
    View All 25 Advanced Conditions
    View All 107 Experienced Conditions
    Want to save this doctor for later?
    Sign Up
    Is this your doctor?
    Find A Second Opinion
    Not sure about your diagnosis?
    Check Your Symptoms
     
     
     
     
    Learn about our expert tiers
    Learn More
    Are you the provider on this profile?
    Claim Profile